Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
Antiviral Res
    June 2024
  1. ZHAI G, Fu W, Yuan S, Sun P, et al
    A fusion protein approach to integrate antiviral and anti-inflammatory activities for developing new therapeutics against influenza A virus infection.
    Antiviral Res. 2024 Jun 9:105924. doi: 10.1016/j.antiviral.2024.105924.
    >> Share

  2. LI J, Cui H, Yao Y, Niu J, et al
    Anti-influenza activity of CPAVM1 protease secreted by Bacillus subtilis LjM2.
    Antiviral Res. 2024 Jun 6:105919. doi: 10.1016/j.antiviral.2024.105919.
    >> Share

  3. GUO M, Peng J, Guo P, Wang Q, et al
    Inhalation of 2, 4-di-tert-butylphenol-Loaded micelles suppresses respiratory syncytial virus infection in mice.
    Antiviral Res. 2024;226:105880.
    >> Share

    May 2024
  4. FRANCO-MAY DA, Gomez-Carballo J, Barrera-Badillo G, Cruz-Ortiz MN, et al
    Low antiviral resistance in Influenza A and B viruses isolated in Mexico from 2010 to 2023.
    Antiviral Res. 2024;227:105918.
    >> Share

    April 2024
  5. LIU X, Wang Y, Sun L, Xiao G, et al
    Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD.
    Antiviral Res. 2024 Apr 29:105898. doi: 10.1016/j.antiviral.2024.105898.
    >> Share

  6. ARDUINO I, Francese R, Civra A, Feyles E, et al
    Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry.
    Antiviral Res. 2024;226:105897.
    >> Share

  7. GLITSCHER M, Benz NI, Sabino C, Murra RO, et al
    Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Antiviral Res. 2024;226:105891.
    >> Share

  8. TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al
    Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
    Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879.
    >> Share

    March 2024
  9. RAHA JR, Kim KH, Bhatnagar N, Liu R, et al
    Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice.
    Antiviral Res. 2024;225:105877.
    >> Share

  10. KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al
    Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Antiviral Res. 2024;225:105874.
    >> Share

  11. SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al
    New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871.
    >> Share

  12. PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al
    Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
    Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869.
    >> Share

  13. MOON C, Porges E, Roberts A, Bacon J, et al
    A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
    Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
    >> Share

  14. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
    SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
    Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
    >> Share

  15. WANG W, Wang S, Meng X, Zhao Y, et al
    A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
    Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
    >> Share

  16. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
    Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
    Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
    >> Share

  17. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
    The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
    Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
    >> Share

    February 2024
  18. GOTO T, Kawai N, Bando T, Takasaki Y, et al
    Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.
    Antiviral Res. 2024;224:105853.
    >> Share

  19. NOBORI H, Baba K, Kuroda T, Baba K, et al
    Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Antiviral Res. 2024;224:105852.
    >> Share

  20. LI H, Sun M, Lei F, Liu J, et al
    Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a potential candidate against SARS-cov-2 infection.
    Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841.
    >> Share

  21. BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al
    The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.
    Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837.
    >> Share

  22. ZHANG X, Xia Y, Li P, Wu Z, et al
    Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus.
    Antiviral Res. 2024 Feb 11:105822. doi: 10.1016/j.antiviral.2024.105822.
    >> Share

  23. SINHA D, Yaugel-Novoa M, Waeckel L, Paul S, et al
    Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses.
    Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823.
    >> Share

  24. IZMAILYAN R, Matevosyan M, Khachatryan H, Shavina A, et al
    Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results.
    Antiviral Res. 2024;222:105818.
    >> Share

  25. RICHTER M, Doring K, Blaas D, Riabova O, et al
    Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance.
    Antiviral Res. 2024;222:105810.
    >> Share

  26. LOAIZA RA, Ramirez RA, Sepulveda-Alfaro J, Ramirez MA, et al
    A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
    Antiviral Res. 2024;222:105783.
    >> Share

    January 2024
  27. WINIGER RR, Perez L
    Therapeutic antibodies and alternative formats against SARS-CoV-2.
    Antiviral Res. 2024 Jan 31:105820. doi: 10.1016/j.antiviral.2024.105820.
    >> Share

  28. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
    Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
    Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
    >> Share

  29. BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al
    Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
    Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813.
    >> Share

  30. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
    An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
    Antiviral Res. 2024;222:105815.
    >> Share

  31. MATTHYS A, Saelens X
    Promises and challenges of single-domain antibodies to control influenza.
    Antiviral Res. 2024 Jan 12:105807. doi: 10.1016/j.antiviral.2024.105807.
    >> Share

  32. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al
    TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
    Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
    >> Share

  33. ZOU G, Cao S, Gao Z, Yie J, et al
    Current state and challenges in respiratory syncytial virus drug discovery and development.
    Antiviral Res. 2024;221:105791.
    >> Share

    December 2023
  34. CHEN X, Tian L, Zhang L, Gao W, et al
    Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein.
    Antiviral Res. 2023;221:105790.
    >> Share

  35. SUN X, Ma H, Wang X, Bao Z, et al
    Broadly neutralizing antibodies to combat influenza virus infection.
    Antiviral Res. 2023 Dec 23:105785. doi: 10.1016/j.antiviral.2023.105785.
    >> Share

  36. AKSU M, Kumar P, Guttler T, Taxer W, et al
    Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
    Antiviral Res. 2023 Dec 6:105778. doi: 10.1016/j.antiviral.2023.105778.
    >> Share

  37. ZUR M, Peselev T, Yanko S, Rotshild V, et al
    Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768.
    >> Share

    November 2023
  38. WANG S, Cui H, Zhang C, Li W, et al
    Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.
    Antiviral Res. 2023 Nov 28:105765. doi: 10.1016/j.antiviral.2023.105765.
    >> Share

  39. GOMEZ-CARBALLA A, Albericio G, Montoto-Louzao J, Perez P, et al
    Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
    Antiviral Res. 2023 Nov 20:105760. doi: 10.1016/j.antiviral.2023.105760.
    >> Share

  40. WU CY, Tseng YC, Kao SE, Wu LY, et al
    Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA(stem)-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses.
    Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759.
    >> Share

  41. ZHANG QY, Zhang HQ, Zhang YN, Zhang ZR, et al
    Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
    Antiviral Res. 2023 Nov 18:105757. doi: 10.1016/j.antiviral.2023.105757.
    >> Share

  42. SADHU S, Dandotiya J, Dalal R, Khatri R, et al
    Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
    Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743.
    >> Share

  43. HSIEH HC, Chen CC, Chou PH, Liu WC, et al
    Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
    Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752.
    >> Share

  44. SU WC, Chen ZY, Chang YS, Jeng KS, et al
    Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization.
    Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744.
    >> Share

  45. KIM DG, Kim U, Park IH, Ryu B, et al
    A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants.
    Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.
    >> Share

  46. LUGANINI A, Sibille G, Pavan M, Mello Grand M, et al
    Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication.
    Antiviral Res. 2023;219:105734.
    >> Share

    October 2023
  47. DEMIAN WL, Jacob RA, Cormier O, Nazli A, et al
    ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2.
    Antiviral Res. 2023 Oct 18:105736. doi: 10.1016/j.antiviral.2023.105736.
    >> Share

  48. PALLA SR, Li CW, Chao TL, Lo HV, et al
    Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
    Antiviral Res. 2023 Oct 17:105735. doi: 10.1016/j.antiviral.2023.105735.
    >> Share

  49. KONKEL R, Milewska A, Do NDT, Barreto Duran E, et al
    Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411.
    Antiviral Res. 2023 Oct 12:105731. doi: 10.1016/j.antiviral.2023.105731.
    >> Share

    September 2023
  50. GAO R, Pascua PNQ, Nguyen HT, Chesnokov A, et al
    New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses.
    Antiviral Res. 2023;218:105719.
    >> Share

  51. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
    Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
    Antiviral Res. 2023 Sep 8:105716. doi: 10.1016/j.antiviral.2023.105716.
    >> Share

    August 2023
  52. IVASHCHENKO AA, Jones JC, Shkil DO, Ivanenkov YA, et al
    Resistance profiles for the investigational neuraminidase inhibitor AV5080 in influenza A and B viruses.
    Antiviral Res. 2023;217:105701.
    >> Share

  53. VANDERLINDEN E, Boonen A, Noppen S, Schoofs G, et al
    PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
    Antiviral Res. 2023;217:105700.
    >> Share

  54. CORONA A, Madia VN, De Santis R, Manelfi C, et al
    Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
    Antiviral Res. 2023;217:105697.
    >> Share

    July 2023
  55. NGUYEN HT, Chesnokov A, De La Cruz J, Pascua PNQ, et al
    Antiviral susceptibility of clade highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.
    Antiviral Res. 2023 Jul 24:105679. doi: 10.1016/j.antiviral.2023.105679.
    >> Share

  56. SPENGLER JR, Carter K, Delang L, Durantel D, et al
    Meeting report: 36th international conference on antiviral research in Lyon, France, March 13-17, 2023.
    Antiviral Res. 2023 Jul 24:105678. doi: 10.1016/j.antiviral.2023.105678.
    >> Share

  57. SUPREWICZ L, Szczepanski A, Lenart M, Piktel E, et al
    Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response.
    Antiviral Res. 2023 Jul 20:105676. doi: 10.1016/j.antiviral.2023.105676.
    >> Share

  58. BOWDEN-REID E, Ledger S, Zhang Y, Di Giallonardo F, et al
    Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677.
    >> Share

  59. TAKASHITA E, Fujisaki S, Morita H, Nagata S, et al
    Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
    Antiviral Res. 2023;216:105671.
    >> Share

  60. JEONG JH, Choi JH, Kim BK, Min SC, et al
    Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
    Antiviral Res. 2023 Jul 10:105669. doi: 10.1016/j.antiviral.2023.105669.
    >> Share

  61. FENG Y, Yang Y, Zou S, Qiu S, et al
    Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
    Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666.
    >> Share

    June 2023
  62. MU S, Zou X, Wang Y, Deng X, et al
    The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza.
    Antiviral Res. 2023 Jun 25:105657. doi: 10.1016/j.antiviral.2023.105657.
    >> Share

  63. CAI H, Yan J, Liu S, Li P, et al
    Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
    Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659.
    >> Share

  64. MILAN BONOTTO R, Mitrovic A, Sosic I, Martinez-Orellana P, et al
    Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
    Antiviral Res. 2023;216:105655.
    >> Share

  65. JUNG HE, Ku KB, Kang BH, Park JH, et al
    Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Antiviral Res. 2023;216:105656.
    >> Share

  66. CHANG YJ, Le UNP, Liu JJ, Li SR, et al
    Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
    Antiviral Res. 2023 Jun 13:105653. doi: 10.1016/j.antiviral.2023.105653.
    >> Share

  67. ZHANG J, Nian X, Liu B, Zhang Z, et al
    Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study.
    Antiviral Res. 2023;216:105639.
    >> Share

    May 2023
  68. WU CY, Kao SE, Tseng YC, Lin YP, et al
    Pilot-scale production of inactivated monoglycosylated split H(1)N(1) influenza virus vaccine provides cross-strain protection against influenza viruses.
    Antiviral Res. 2023 May 30:105640. doi: 10.1016/j.antiviral.2023.105640.
    >> Share

  69. WANG X, Lin L, Chen Z, Si W, et al
    Mutations at site 207 of influenza a virus NS1 protein switch its function in regulating RIG-I-like receptors mediated antiviral responses.
    Antiviral Res. 2023 May 23:105641. doi: 10.1016/j.antiviral.2023.105641.
    >> Share

  70. DRIOUICH JS, Bernadin O, Touret F, de Lamballerie X, et al
    Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
    Antiviral Res. 2023 May 17:105638. doi: 10.1016/j.antiviral.2023.105638.
    >> Share

  71. HUANG X, Fan W, Sun J, Yang J, et al
    SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril.
    Antiviral Res. 2023 May 17:105636. doi: 10.1016/j.antiviral.2023.105636.
    >> Share

  72. HU J, Zhang L, Zheng X, Wang G, et al
    Long noncoding RNA #61 exerts a broad anti-influenza a virus effect by its long arm rings.
    Antiviral Res. 2023 May 15:105637. doi: 10.1016/j.antiviral.2023.105637.
    >> Share

  73. YANG X, Long F, Jia W, Zhang M, et al
    Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export.
    Antiviral Res. 2023 May 14:105635. doi: 10.1016/j.antiviral.2023.105635.
    >> Share

    April 2023
  74. CHO J, Shin Y, Yang JS, Kim JW, et al
    Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2023;214:105609.
    >> Share

  75. LI Y, Wang K, Sun H, Wu S, et al
    Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
    Antiviral Res. 2023 Apr 17:105606. doi: 10.1016/j.antiviral.2023.105606.
    >> Share

  76. CONG Y, Lee JH, Perry DL, Cooper K, et al
    Longitudinal analyses using (18)F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
    Antiviral Res. 2023 Apr 15:105605. doi: 10.1016/j.antiviral.2023.105605.
    >> Share

    March 2023
  77. SON S, Ahn SB, Kim G, Jang Y, et al
    Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice.
    Antiviral Res. 2023;213:105591.
    >> Share

  78. BILLS C, Xie X, Shi PY
    The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
    Antiviral Res. 2023;213:105590.
    >> Share

  79. CONG Y, Mucker EM, Perry DL, Dixit S, et al
    Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
    Antiviral Res. 2023;213:105589.
    >> Share

  80. YANG Y, Cao L, Yan M, Zhou J, et al
    Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Antiviral Res. 2023 Mar 28:105586. doi: 10.1016/j.antiviral.2023.105586.
    >> Share

  81. VANHULLE E, Doijen J, Stroobants J, Provinciael B, et al
    Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants.
    Antiviral Res. 2023;213:105587.
    >> Share

  82. DICHTL S, Diem G, Jager M, Zaderer V, et al
    Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
    Antiviral Res. 2023 Mar 23:105581. doi: 10.1016/j.antiviral.2023.105581.
    >> Share

  83. ALVES RPDS, Wang YT, Mikulski Z, McArdle S, et al
    SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model.
    Antiviral Res. 2023 Mar 18:105580. doi: 10.1016/j.antiviral.2023.105580.
    >> Share

  84. LU C, Zhang Y, Liu X, Hou F, et al
    Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.
    Antiviral Res. 2023;212:105556.
    >> Share

  85. KIM JW, Heo K, Kim HJ, Yoo Y, et al
    Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Antiviral Res. 2023;212:105576.
    >> Share

  86. SHEKUNOV EV, Zlodeeva PD, Efimova SS, Muryleva AA, et al
    Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.
    Antiviral Res. 2023;212:105575.
    >> Share

  87. ISSMAIL L, Ramsbeck D, Jager C, Henning T, et al
    Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus.
    Antiviral Res. 2023;211:105547.
    >> Share

  88. HU Y, Zhu Y, Yu Y, Liu N, et al
    Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
    Antiviral Res. 2023;212:105571.
    >> Share

    February 2023
  89. XIAO Y, Yan Y, Chang L, Ji H, et al
    CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation.
    Antiviral Res. 2023 Feb 18:105558. doi: 10.1016/j.antiviral.2023.105558.
    >> Share

  90. LI J, Wang Y, Solanki K, Atre R, et al
    Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
    Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555.
    >> Share

  91. MERINO VF, Yan Y, Ordonez AA, Bullen CK, et al
    Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells.
    Antiviral Res. 2023;211:105550.
    >> Share

  92. KURHADE C, Xie X, Shi PY
    Reverse genetic systems of SARS-CoV-2 for antiviral research.
    Antiviral Res. 2023;210:105486.
    >> Share

    January 2023
  93. ZHU Y, Li M, Liu N, Wu T, et al
    Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
    Antiviral Res. 2023;211:105541.
    >> Share

  94. BASILE A, Zannella C, De Marco M, Sanna G, et al
    Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody.
    Antiviral Res. 2023;211:105546.
    >> Share

  95. HU L, Lao G, Liu R, Feng J, et al
    Corrigendum to "The race toward a universal influenza vaccine: Front runners and the future directions" [Antivir. Res. (2022) 105505].
    Antiviral Res. 2023 Jan 15:105543. doi: 10.1016/j.antiviral.2023.105543.
    >> Share

    December 2022
  96. SPENGLER JR, Welch SR, Deval J, Gentry BG, et al
    Meeting report: 35th international conference on antiviral research in Seattle, WA, USA - March 21-25, 2022.
    Antiviral Res. 2022 Dec 31:105521. doi: 10.1016/j.antiviral.2022.105521.
    >> Share

  97. CHISTOV AA, Chumakov SP, Mikhnovets IE, Nikitin TD, et al
    5-(Perylen-3-ylethynyl)uracil as an antiviral scaffold: Potent suppression of enveloped virus reproduction by 3-methyl derivatives in vitro.
    Antiviral Res. 2022 Dec 26:105508. doi: 10.1016/j.antiviral.2022.105508.
    >> Share

  98. LIM SP
    Targeting SARS-CoV-2 and host cell receptor interactions.
    Antiviral Res. 2022 Dec 26:105514. doi: 10.1016/j.antiviral.2022.105514.
    >> Share

  99. HU L, Lao G, Liu R, Feng J, et al
    The race toward a universal influenza vaccine: Front runners and the future directions.
    Antiviral Res. 2022 Dec 24:105505. doi: 10.1016/j.antiviral.2022.105505.
    >> Share

  100. HU L, Tang Y, Mei L, Liang M, et al
    A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly.
    Antiviral Res. 2022;209:105509.
    >> Share

  101. JONES JC, Yen HL, Adams P, Armstrong K, et al
    Influenza antivirals and their role in pandemic preparedness.
    Antiviral Res. 2022 Dec 23:105499. doi: 10.1016/j.antiviral.2022.105499.
    >> Share

  102. TNG DJH, Low JGH
    Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.
    Antiviral Res. 2022 Dec 22:105488. doi: 10.1016/j.antiviral.2022.105488.
    >> Share

  103. ZHANG YN, Zhang HQ, Wang GF, Zhang ZR, et al
    Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster.
    Antiviral Res. 2022;209:105507.
    >> Share

  104. SHANNON A, Canard B
    Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.
    Antiviral Res. 2022 Dec 21:105501. doi: 10.1016/j.antiviral.2022.105501.
    >> Share

  105. CHIU W, Schepers J, Francken T, Vangeel L, et al
    Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
    Antiviral Res. 2022 Dec 21:105506. doi: 10.1016/j.antiviral.2022.105506.
    >> Share

  106. TANG Y, Su R, Gu Q, Hu Y, et al
    PI3K/AKT-mediated autophagy inhibition facilitates mast cell activation to enhance severe inflammatory lung injury in influenza A virus- and secondary Staphylococcus aureus-infected mice.
    Antiviral Res. 2022 Dec 19:105502. doi: 10.1016/j.antiviral.2022.105502.
    >> Share

  107. JOHNSON DM, Brasel T, Massey S, Garron T, et al
    Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Antiviral Res. 2022 Dec 16:105492. doi: 10.1016/j.antiviral.2022.105492.
    >> Share

  108. PEREZ-VARGAS J, Shapira T, Olmstead AD, Villanueva I, et al
    Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
    Antiviral Res. 2022 Dec 8:105484. doi: 10.1016/j.antiviral.2022.105484.
    >> Share

  109. HASHIZUME M, Takashima A, Ono C, Okamoto T, et al
    Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
    Antiviral Res. 2022 Dec 5:105481. doi: 10.1016/j.antiviral.2022.105481.
    >> Share

  110. YAO Y, Sun H, Chen Y, Tian L, et al
    RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region.
    Antiviral Res. 2022;209:105478.
    >> Share

    November 2022
  111. JEONG K, Chang J, Park SM, Kim J, et al
    Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay.
    Antiviral Res. 2022 Nov 23:105473. doi: 10.1016/j.antiviral.2022.105473.
    >> Share

  112. FAIST A, Schloer S, Mecate-Zambrano A, Janowski J, et al
    Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.
    Antiviral Res. 2022 Nov 21:105475. doi: 10.1016/j.antiviral.2022.105475.
    >> Share

  113. HUI X, Yu X, Huang K, Xu T, et al
    In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection.
    Antiviral Res. 2022 Nov 16:105465. doi: 10.1016/j.antiviral.2022.105465.
    >> Share

  114. YANG F, Yan S, Zhu L, Wang FXC, et al
    Evaluation of panel of neutralising murine monoclonal antibodies and a humanised bispecific antibody against influenza A(H1N1)pdm09 virus infection in a mouse model.
    Antiviral Res. 2022 Nov 14:105462. doi: 10.1016/j.antiviral.2022.105462.
    >> Share

  115. FABREGA-FERRER M, Herrera-Morande A, Muriel-Goni S, Perez-Saavedra J, et al
    Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
    Antiviral Res. 2022;208:105458.
    >> Share

  116. PATEL MC, Flanigan D, Feng C, Chesnokov A, et al
    An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance.
    Antiviral Res. 2022 Nov 1:105457. doi: 10.1016/j.antiviral.2022.105457.
    >> Share

    October 2022
  117. PASCUA PNQ, Jones JC, Webby RJ, Govorkova EA, et al
    Effect of E23G/K, F36V, N37T, E119D, and E199G polymerase acidic protein substitutions on the replication and baloxavir susceptibility of influenza B viruses.
    Antiviral Res. 2022 Oct 31:105455. doi: 10.1016/j.antiviral.2022.105455.
    >> Share

  118. SHANG W, Dai W, Yao C, Xu L, et al
    In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2.
    Antiviral Res. 2022;208:105450.
    >> Share

  119. VARRICCHIO C, Mathez G, Pillonel T, Bertelli C, et al
    Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting.
    Antiviral Res. 2022;208:105452.
    >> Share

  120. RADILOVA K, Zima V, Kral M, Machara A, et al
    Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase PA-PB1 subunit interaction.
    Antiviral Res. 2022 Oct 17:105449. doi: 10.1016/j.antiviral.2022.105449.
    >> Share

  121. ZHU Y, Hu Y, Liu N, Chong H, et al
    Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Antiviral Res. 2022;208:105445.
    >> Share

  122. KIM TY, Kim JY, Kwon HC, Jeon S, et al
    Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibit the infection of SARS-CoV-2 variants and syncytium formation.
    Antiviral Res. 2022 Oct 14:105428. doi: 10.1016/j.antiviral.2022.105428.
    >> Share

  123. BRAY M
    Antiviral Research: At age 41, a transition.
    Antiviral Res. 2022 Oct 14:105447. doi: 10.1016/j.antiviral.2022.105447.
    >> Share

  124. JEONG JH, Chokkakula S, Min SC, Kim BK, et al
    Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
    Antiviral Res. 2022;208:105430.
    >> Share

  125. ZHU Y, Binder J, Yurgelonis I, Rai D, et al
    Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study.
    Antiviral Res. 2022 Oct 5:105429. doi: 10.1016/j.antiviral.2022.105429.
    >> Share

    September 2022
  126. MA L, Li Q, Xie Y, Jianyuan Zhao, et al
    Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro).
    Antiviral Res. 2022 Sep 22:105419. doi: 10.1016/j.antiviral.2022.105419.
    >> Share

  127. CHENG Y, Yang C, Li Z, Li X, et al
    Anti-influenza virus activity of the REV-ERBalpha agonist SR9009 and related analogues.
    Antiviral Res. 2022 Sep 16:105418. doi: 10.1016/j.antiviral.2022.105418.
    >> Share

    August 2022
  128. DEMAREST JF, Kienle M, Boytz R, Ayres M, et al
    Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
    Antiviral Res. 2022 Aug 27:105403. doi: 10.1016/j.antiviral.2022.105403.
    >> Share

  129. LU L, Peng Y, Yao H, Wang Y, et al
    Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro.
    Antiviral Res. 2022 Aug 16:105389. doi: 10.1016/j.antiviral.2022.105389.
    >> Share

  130. KOMENO T, Furuta Y, Nakajima N, Tani H, et al
    Analysis of the responsible site for favipiravir resistance in RNA-dependent RNA polymerase of influenza virus A/PR/8/34 (H1N1) using site-directed mutagenesis.
    Antiviral Res. 2022 Aug 2:105387. doi: 10.1016/j.antiviral.2022.105387.
    >> Share

  131. CIVRA A, Costantino M, Cavalli R, Adami M, et al
    27-Hydroxycholesterol inhibits rhinovirus replication in vitro and on human nasal and bronchial histocultures without selecting viral resistant variants.
    Antiviral Res. 2022;204:105368.
    >> Share

    July 2022
  132. LI M, Chen J, Liu Y, Zhao J, et al
    Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.
    Antiviral Res. 2022 Jul 30:105383. doi: 10.1016/j.antiviral.2022.105383.
    >> Share

  133. SAMRAT SK, Xu J, Xie X, Gianti E, et al
    Allosteric inhibitors of the main protease of SARS-CoV-2.
    Antiviral Res. 2022;205:105381.
    >> Share

  134. BEZERRA BB, Silva GPDD, Antunes Coelho SV, Correa IA, et al
    Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines.
    Antiviral Res. 2022 Jul 4:105373. doi: 10.1016/j.antiviral.2022.105373.
    >> Share

  135. OHASHI H, Hishiki T, Akazawa D, Kim KS, et al
    Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
    Antiviral Res. 2022 Jul 4:105372. doi: 10.1016/j.antiviral.2022.105372.
    >> Share

    June 2022
  136. KIM EH, Lee BW, Ryu B, Cho HM, et al
    Inhibition of a broad range of SARS-CoV-2 variants by antiviral phytochemicals in hACE2 mice.
    Antiviral Res. 2022;204:105371.
    >> Share

  137. SEEPHETDEE C, Bhukhai K, Buasri N, Leelukkanaveera P, et al
    A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
    Antiviral Res. 2022 Jun 27:105370. doi: 10.1016/j.antiviral.2022.105370.
    >> Share

  138. JONES JC, Rovito SW, Penaflor MK, Webby RJ, et al
    Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
    Antiviral Res. 2022 Jun 20:105369. doi: 10.1016/j.antiviral.2022.105369.
    >> Share

  139. KARIM M, Saul S, Ghita L, Sahoo MK, et al
    Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies.
    Antiviral Res. 2022 Jun 20:105367. doi: 10.1016/j.antiviral.2022.105367.
    >> Share

  140. ZHOU M, Liu Y, Cao J, Dong S, et al
    Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters.
    Antiviral Res. 2022 Jun 19:105365. doi: 10.1016/j.antiviral.2022.105365.
    >> Share

  141. HERNANDEZ S, Feracci M, De Jesus CT, El Kazzi P, et al
    Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay.
    Antiviral Res. 2022 Jun 15:105364. doi: 10.1016/j.antiviral.2022.105364.
    >> Share

  142. MELO-FILHO CC, Bobrowski T, Martin HJ, Sessions Z, et al
    Conserved coronavirus proteins as targets of broad-spectrum antivirals.
    Antiviral Res. 2022 Jun 9:105360. doi: 10.1016/j.antiviral.2022.105360.
    >> Share

  143. MERCORELLI B, Desantis J, Celegato M, Bazzacco A, et al
    Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization.
    Antiviral Res. 2022;204:105350.
    >> Share

    May 2022
  144. PRASHAR P, Swain S, Adhikari N, Aryan P, et al
    A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies.
    Antiviral Res. 2022 May 28:105349. doi: 10.1016/j.antiviral.2022.105349.
    >> Share

  145. LIN Q, Lu C, Hong Y, Li R, et al
    Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
    Antiviral Res. 2022 May 20:105345. doi: 10.1016/j.antiviral.2022.105345.
    >> Share

  146. ROY A, Alhammad YM, McDonald P, Johnson DK, et al
    Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Antiviral Res. 2022 May 19:105344. doi: 10.1016/j.antiviral.2022.105344.
    >> Share

  147. WEIL T, Lawrenz J, Seidel A, Munch J, et al
    Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.
    Antiviral Res. 2022 May 19:105343. doi: 10.1016/j.antiviral.2022.105343.
    >> Share

  148. VANHULLE E, Stroobants J, Provinciael B, Camps A, et al
    SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
    Antiviral Res. 2022 May 17:105342. doi: 10.1016/j.antiviral.2022.105342.
    >> Share

  149. FINDLAY-WILSON S, Easterbrook L, Smith S, Pope N, et al
    Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
    Antiviral Res. 2022 May 6:105332. doi: 10.1016/j.antiviral.2022.105332.
    >> Share

  150. PITTS J, Babusis D, Vermillion MS, Subramanian R, et al
    Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
    Antiviral Res. 2022 May 4:105329. doi: 10.1016/j.antiviral.2022.105329.
    >> Share

  151. ZHAO L, Yan Y, Dai Q, Wang Z, et al
    The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection.
    Antiviral Res. 2022;201:105296.
    >> Share

    April 2022
  152. FOO CS, Abdelnabi R, Kaptein SJF, Zhang X, et al
    HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
    Antiviral Res. 2022;202:105311.
    >> Share

  153. VANMECHELEN B, Stroobants J, Chiu W, Schepers J, et al
    Identification of novel Ebola virus inhibitors using biologically contained virus.
    Antiviral Res. 2022;200:105294.
    >> Share

    March 2022
  154. WAGATSUMA K, Saito R, Chon I, Phyu WW, et al
    Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
    Antiviral Res. 2022;201:105310.
    >> Share

  155. HUANG J, Liu X, Sun Y, Huang C, et al
    Porcine beta-defensin 2 confers enhanced resistance to swine flu infection in transgenic pigs and alleviates swine influenza virus-induced apoptosis possibly through interacting with host SLC25A4.
    Antiviral Res. 2022;201:105292.
    >> Share

  156. UENO M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, et al
    Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
    Antiviral Res. 2022;201:105297.
    >> Share

  157. BROWN SK, Tseng YY, Aziz A, Baz M, et al
    Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
    Antiviral Res. 2022;200:105280.
    >> Share

  158. LAI GC, Chao TL, Lin SY, Kao HC, et al
    Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.
    Antiviral Res. 2022;200:105290.
    >> Share

  159. GOVORKOVA EA, Takashita E, Daniels RS, Fujisaki S, et al
    Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
    Antiviral Res. 2022 Mar 12:105281. doi: 10.1016/j.antiviral.2022.105281.
    >> Share

  160. PASQUERO S, Gugliesi F, Griffante G, Dell'Oste V, et al
    Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2.
    Antiviral Res. 2022;200:105278.
    >> Share

  161. SCHOLLE MD, O'Kane PT, Dib S, Gurard-Levin ZA, et al
    Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
    Antiviral Res. 2022;200:105279.
    >> Share

  162. CHEN KY, Krischuns T, Varga LO, Harigua-Souiai E, et al
    A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
    Antiviral Res. 2022 Mar 9:105272. doi: 10.1016/j.antiviral.2022.105272.
    >> Share

  163. TANAKA T, Saito A, Suzuki T, Miyamoto Y, et al
    Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening.
    Antiviral Res. 2022;199:105268.
    >> Share

    February 2022
  164. TSAI TI, Khalili JS, Gilchrist M, Waight AB, et al
    ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern.
    Antiviral Res. 2022 Feb 28:105271. doi: 10.1016/j.antiviral.2022.105271.
    >> Share

  165. SACHSE M, Tenorio R, Fernandez de Castro I, Munoz-Basagoiti J, et al
    Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis.
    Antiviral Res. 2022 Feb 26:105270. doi: 10.1016/j.antiviral.2022.105270.
    >> Share

    January 2022
  166. ZHAO J, Liu Q, Yi D, Li Q, et al
    5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
    Antiviral Res. 2022 Jan 28:105254. doi: 10.1016/j.antiviral.2022.105254.
    >> Share

  167. VANGEEL L, Chiu W, De Jonghe S, Maes P, et al
    Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
    Antiviral Res. 2022 Jan 24:105252. doi: 10.1016/j.antiviral.2022.105252.
    >> Share

  168. ABDELNABI R, Foo CS, Zhang X, Lemmens V, et al
    The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.
    Antiviral Res. 2022 Jan 20:105253. doi: 10.1016/j.antiviral.2022.105253.
    >> Share

  169. FOCOSI D, Maggi F, McConnell S, Casadevall A, et al
    Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.
    Antiviral Res. 2022;198:105247.
    >> Share

  170. WILLIAMSON BN, Perez-Perez L, Schwarz B, Feldmann F, et al
    Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2.
    Antiviral Res. 2022 Jan 12:105246. doi: 10.1016/j.antiviral.2022.105246.
    >> Share

    December 2021
  171. MCKIMM-BRESCHKIN JL, Hay AJ, Cao B, Cox RJ, et al
    COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference.
    Antiviral Res. 2021 Dec 18:105227. doi: 10.1016/j.antiviral.2021.105227.
    >> Share

  172. BHATNAGAR N, Kim KH, Subbiah J, Park BR, et al
    Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.
    Antiviral Res. 2021 Dec 18:105229. doi: 10.1016/j.antiviral.2021.105229.
    >> Share

    November 2021
  173. COCHIN M, Touret F, Driouich JS, Moureau G, et al
    Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
    Antiviral Res. 2021;197:105212.
    >> Share

  174. ZHAO J, Zhang G, Zhang Y, Yi D, et al
    2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
    Antiviral Res. 2021;196:105209.
    >> Share

  175. VANDERLINDEN E, Marchand A, Van Berwaer R, van Dam W, et al
    A broad influenza virus inhibitor acting via IMP dehydrogenase and in synergism with ribavirin.
    Antiviral Res. 2021 Nov 15:105208. doi: 10.1016/j.antiviral.2021.105208.
    >> Share

  176. SVILENOV HL, Sacherl J, Reiter A, Wolff LS, et al
    Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
    Antiviral Res. 2021 Nov 10:105197. doi: 10.1016/j.antiviral.2021.105197.
    >> Share

  177. QIU H, Yuan XY, Cabral T, Manguiat K, et al
    Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
    Antiviral Res. 2021 Nov 8:105206. doi: 10.1016/j.antiviral.2021.105206.
    >> Share

    August 2021
  178. GARCIA-DORIVAL I, Cuesta-Geijo MA, Barrado-Gil L, Galindo I, et al
    Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target.
    Antiviral Res. 2021 Aug 24:105167. doi: 10.1016/j.antiviral.2021.105167.
    >> Share

  179. ESCAFFRE O, Freiberg AN
    Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells.
    Antiviral Res. 2021 Aug 9:105162. doi: 10.1016/j.antiviral.2021.105162.
    >> Share

  180. LEACH A, Ilca FT, Akbar Z, Ferrari M, et al
    A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Antiviral Res. 2021 Aug 7:105147. doi: 10.1016/j.antiviral.2021.105147.
    >> Share

  181. ISON MG, Hayden FG, Hay AJ, Gubareva LV, et al
    Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
    Antiviral Res. 2021;194:105158.
    >> Share

    July 2021
  182. KASPRZYK R, Spiewla TJ, Smietanski M, Golojuch S, et al
    Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.
    Antiviral Res. 2021;193:105142.
    >> Share

  183. TOURET F, Driouich JS, Cochin M, Petit PR, et al
    Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
    Antiviral Res. 2021;193:105137.
    >> Share

  184. GAN ES, Syenina A, Linster M, Ng B, et al
    A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
    Antiviral Res. 2021;193:105138.
    >> Share

  185. PARK JH, Kim B, Antigua KJC, Jeong JH, et al
    Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model.
    Antiviral Res. 2021;193:105126.
    >> Share

  186. PERSOONS L, Vanderlinden E, Vangeel L, Wang X, et al
    Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
    Antiviral Res. 2021 Jul 1:105127. doi: 10.1016/j.antiviral.2021.105127.
    >> Share

    June 2021
  187. DO TND, Donckers K, Vangeel L, Chatterjee AK, et al
    A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
    Antiviral Res. 2021 Jun 26:105122. doi: 10.1016/j.antiviral.2021.105122.
    >> Share

  188. KASHYAP T, Murray J, Walker CJ, Chang H, et al
    Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
    Antiviral Res. 2021 Jun 19:105115. doi: 10.1016/j.antiviral.2021.105115.
    >> Share

    May 2021
  189. CHONG Y, Kawai N, Tani N, Bando T, et al
    Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Antiviral Res. 2021;192:105092.
    >> Share

    April 2021
  190. SVYATCHENKO SV, Goncharova NI, Marchenko VY, Kolosova NP, et al
    An influenza A(H5N8) virus isolated during an outbreak at a poultry farm in Russia in 2017 has an N294S substitution in the neuraminidase and shows reduced susceptibility to oseltamivir.
    Antiviral Res. 2021 Apr 29:105079. doi: 10.1016/j.antiviral.2021.105079.
    >> Share

  191. ZHAO J, Guo S, Yi D, Li Q, et al
    A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Antiviral Res. 2021;190:105078.
    >> Share

  192. DU R, Cooper L, Chen Z, Lee H, et al
    Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CL(pro).
    Antiviral Res. 2021 Apr 16:105075. doi: 10.1016/j.antiviral.2021.105075.
    >> Share

    March 2021
  193. CICCOSANTI F, Di Rienzo M, Romagnoli A, Colavita F, et al
    Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.
    Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064.
    >> Share

  194. ROOSENHOFF R, Schutten M, Reed V, Clinch B, et al
    Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
    Antiviral Res. 2021 Mar 10:105060. doi: 10.1016/j.antiviral.2021.105060.
    >> Share

  195. MILANI M, Donalisio M, Bonotto RM, Schneider E, et al
    Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
    Antiviral Res. 2021 Mar 10:105055. doi: 10.1016/j.antiviral.2021.105055.
    >> Share

    February 2021
  196. PATEL MC, Chesnokov A, Jones J, Mishin VP, et al
    Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir.
    Antiviral Res. 2021;188:105035.
    >> Share

  197. HIDEKAZU OSADA, Chon I, Phyu WW, Wagatsuma K, et al
    Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
    Antiviral Res. 2021 Feb 9:105036. doi: 10.1016/j.antiviral.2021.105036.
    >> Share

  198. MARTIN R, Li J, Parvangada A, Perry J, et al
    Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir.
    Antiviral Res. 2021 Feb 4:105033. doi: 10.1016/j.antiviral.2021.105033.
    >> Share

    January 2021
  199. LIU C, Boland S, Scholle MD, Bardiot D, et al
    Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development.
    Antiviral Res. 2021 Jan 27:105020. doi: 10.1016/j.antiviral.2021.105020.
    >> Share

  200. ZHU Q, Zhang Y, Wang L, Yao X, et al
    Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Antiviral Res. 2021 Jan 11:105015. doi: 10.1016/j.antiviral.2021.105015.
    >> Share

  201. DU R, Cheng H, Cui Q, Peet NP, et al
    Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins.
    Antiviral Res. 2021;186:105013.
    >> Share

    November 2020
  202. SVENNINGSEN EB, Thyrsted J, Blay-Cadanet J, Liu H, et al
    Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro.
    Antiviral Res. 2020 Nov 25:104988. doi: 10.1016/j.antiviral.2020.104988.
    >> Share

  203. ZHANG Y, Song W, Chen S, Yuan Z, et al
    A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
    Antiviral Res. 2020 Nov 17:104974. doi: 10.1016/j.antiviral.2020.104974.
    >> Share

  204. HEJDANEK J, Radilova K, Pachl P, Hodek J, et al
    Structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor.
    Antiviral Res. 2020 Nov 6:104971. doi: 10.1016/j.antiviral.2020.104971.
    >> Share

  205. ZARAKET H, Hurt AC, Clinch B, Barr I, et al
    Burden of influenza B virus infection and considerations for clinical management.
    Antiviral Res. 2020 Nov 4:104970. doi: 10.1016/j.antiviral.2020.104970.
    >> Share

    October 2020
  206. CHOI SW, Shin JS, Park SJ, Jung E, et al
    Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Antiviral Res. 2020 Oct 19:104955. doi: 10.1016/j.antiviral.2020.104955.
    >> Share

    September 2020
  207. SAITO R, Osada H, Wagatsuma K, Chon I, et al
    Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Antiviral Res. 2020;183:104951.
    >> Share

  208. THEERAWATANASIRIKUL S, Kuo CJ, Phecharat N, Chootip J, et al
    Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Antiviral Res. 2020 Sep 7:104927. doi: 10.1016/j.antiviral.2020.104927.
    >> Share

  209. GURARD-LEVIN ZA, Liu C, Jekle A, Jaisinghani R, et al
    Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Antiviral Res. 2020 Sep 4:104924. doi: 10.1016/j.antiviral.2020.104924.
    >> Share

    August 2020
  210. KONKOLOVA E, Dejmek M, Hrebabecky H, Sala M, et al
    Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
    Antiviral Res. 2020 Aug 4:104899. doi: 10.1016/j.antiviral.2020.104899.
    >> Share

    July 2020
  211. OKAMOTO M, Toyama M, Baba M
    The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 30:104902. doi: 10.1016/j.antiviral.2020.104902.
    >> Share

  212. PAN X, Zhou P, Fan T, Wu Y, et al
    Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 10:104868. doi: 10.1016/j.antiviral.2020.104868.
    >> Share

  213. SALINAS FM, Nebreda AD, Vazquez L, Gentilini MV, et al
    Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.
    Antiviral Res. 2020;179:104817.
    >> Share

    May 2020
  214. BLOCKUS S, Sake SM, Wetzke M, Grethe C, et al
    Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
    Antiviral Res. 2020;177:104774.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016